Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Guselkumab
DRUG: Midazolam
DRUG: Warfarin
DRUG: Omeprazole
DRUG: Dextromethorphan
DRUG: Caffeine

Sponsor

Janssen Research & Development, LLC